Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor‑infiltrating lymphocytes

Asano,Yuka; Kashiwagi,Shinichiro; Goto,Wataru; Takada,Koji; Takahashi,Katsuyuki; Shibutani,Masatsune; Amano,Ryosuke; Takashima,Tsutomu; Tomita,Shuhei; Hirakawa,Kosei; Ohira,Masaichi

doi:10.3892/mco.2020.2063

Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor‑infiltrating lymphocytes

Authors:
- Yuka Asano
- Shinichiro Kashiwagi
- Wataru Goto
- Koji Takada
- Katsuyuki Takahashi
- Masatsune Shibutani
- Ryosuke Amano
- Tsutomu Takashima
- Shuhei Tomita
- Kosei Hirakawa
- Masaichi Ohira
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan, Department of Pharmacology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan, Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan, Department of Hepato-Biliary‑Pancreatic Surgery, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan
Published online on: June 4, 2020 https://doi.org/10.3892/mco.2020.2063
Pages: 195-202
Copyright: © Asano et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor immune environment not only modulates the effects of immunotherapy, but also the effects of other anticancer drugs and treatment outcomes. These immune responses may be evaluated by measuring tumor‑infiltrating lymphocytes (TILs), which has been frequently verified clinically. In the present study, the prediction of the therapeutic effect of endocrine therapy by TILs on stage IV breast cancer was clinically analyzed. Data from 40 patients who underwent endocrine therapy as the initial drug therapy for stage IV breast cancer were used. The correlation between TILs, evaluated according to standard methods, and prognosis, including the efficacy of endocrine therapy, was investigated retrospectively. Patients with ≥50% lymphocytic infiltration were considered to have lymphocyte‑predominant breast cancer (LPBC). An analysis of outcomes revealed no difference in progression‑free survival (PFS; P=0.171), time to treatment failure (TTF; P=0.054), or overall survival (OS; P=0.641) between the high TIL (>10%) and low TIL (≤10%) groups. Patients with LPBC (≥50%) exhibited a significant prolongation of PFS (P=0.005, log‑rank), TTF (P=0.001) and OS (P=0.027) compared with non‑LPBC patients. On receiver operating characteristics (ROC) curve analysis, better results were obtained with LPBCs [area under the curve (AUC)=0.700] than with TILs (AUC=0.606). The present findings suggest that a high level of lymphocytic infiltration in the tumor stroma may serve as a predictor of the therapeutic efficacy of endocrine therapy in patients with stage IV estrogen receptor‑positive breast cancer.

View Figures

View References

1	Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, et al: Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol. 22:3302–3308. 2004.PubMed/NCBI View Article : Google Scholar
2	Hortobagyi GN: Treatment of breast cancer. N Engl J Med. 339:974–984. 1998.PubMed/NCBI View Article : Google Scholar
3	Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 100:1380–1388. 2008.PubMed/NCBI View Article : Google Scholar
4	Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, et al: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 29:2342–2349. 2011.PubMed/NCBI View Article : Google Scholar
5	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
6	Zitvogel L, Kepp O and Kroemer G: Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 8:151–160. 2011.PubMed/NCBI View Article : Google Scholar
7	Dougan M and Dranoff G: Immune therapy for cancer. Annu Rev Immunol. 27:83–117. 2009.PubMed/NCBI View Article : Google Scholar
8	Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 32:2959–2966. 2014.PubMed/NCBI View Article : Google Scholar
9	Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 33:983–991. 2015.PubMed/NCBI View Article : Google Scholar
10	Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol. 13:228–241. 2016.PubMed/NCBI View Article : Google Scholar
11	Asano Y, Kashiwagi S, Goto W, Kurata K, Noda S, Takashima T, Onoda N, Tanaka S, Ohsawa M and Hirakawa K: Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 103:845–854. 2016.PubMed/NCBI View Article : Google Scholar
12	Asano Y, Kashiwagi S, Onoda N, Kurata K, Morisaki T, Noda S, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K: Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer. 114:14–20. 2016.PubMed/NCBI View Article : Google Scholar
13	Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K: Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 23:1104–1110. 2016.PubMed/NCBI View Article : Google Scholar
14	Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K: Platelet-lymphocyte ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer. PLoS One. 11(e0153459)2016.PubMed/NCBI View Article : Google Scholar
15	Greene FL and Sobin LH: A worldwide approach to the TNM staging system: Collaborative efforts of the AJCC and UICC. J Surg Oncol. 99:269–272. 2009.PubMed/NCBI View Article : Google Scholar
16	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.PubMed/NCBI View Article : Google Scholar
17	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
18	Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015.PubMed/NCBI View Article : Google Scholar
19	Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, et al: Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 132:793–805. 2012.PubMed/NCBI View Article : Google Scholar
20	Mao Y, Qu Q, Zhang Y, Liu J, Chen X and Shen K: The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. PLoS One. 9(e115103)2014.PubMed/NCBI View Article : Google Scholar
21	Loi S: Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J Clin Oncol. 32:2935–2937. 2014.PubMed/NCBI View Article : Google Scholar
22	McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 23:9067–9072. 2005.PubMed/NCBI View Article : Google Scholar
23	Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.PubMed/NCBI View Article : Google Scholar
24	Fridman WH, Pages F, Sautes-Fridman C and Galon J: The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer. 12:298–306. 2012.PubMed/NCBI View Article : Google Scholar
25	Liu H, Zhang T, Ye J, Li H, Huang J, Li X, Wu B, Huang X and Hou J: Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother. 61:1849–1856. 2012.PubMed/NCBI View Article : Google Scholar
26	Kocián P, Šedivcová M, Drgáč J, Cerná K, Hoch J, Kodet R, Bartůňková J, Špíšek R and Fialová A: Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence. Hum Immunol. 72:1022–1028. 2011.PubMed/NCBI View Article : Google Scholar
27	Lee WS, Kang M, Baek JH, Lee JI and Ha SY: Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol. 20:697–702. 2013.PubMed/NCBI View Article : Google Scholar
28	Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y and Hayashi S: Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene. 22:5011–5020. 2003.PubMed/NCBI View Article : Google Scholar
29	Kroemer G, Galluzzi L, Kepp O and Zitvogel L: Immunogenic cell death in cancer therapy. Annu Rev Immunol. 31:51–72. 2013.PubMed/NCBI View Article : Google Scholar
30	Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L and Kroemer G: Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15:3–12. 2008.PubMed/NCBI View Article : Google Scholar
31	Kono K, Mimura K and Kiessling R: Immunogenic tumor cell death induced by chemoradiotherapy: Molecular mechanisms and a clinical translation. Cell Death Dis. 4(e688)2013.PubMed/NCBI View Article : Google Scholar
32	Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, et al: Defective immunogenic cell death of HMGB1-deficient tumors: Compensatory therapy with TLR4 agonists. Cell Death Differ. 21:69–78. 2014.PubMed/NCBI View Article : Google Scholar
33	Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P and de Oliveira CT: Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-Operative ‘Arimidex’ Compared to Tamoxifen (PROACT) trial. Cancer. 106:2095–2103. 2006.PubMed/NCBI View Article : Google Scholar